Format

Send to

Choose Destination
See comment in PubMed Commons below
Jpn J Clin Oncol. 2012 Sep;42(9):800-6. doi: 10.1093/jjco/hys102. Epub 2012 Jul 23.

A retrospective study of S-1 monotherapy as second-line treatment for patients with advanced biliary tract cancer.

Author information

1
Division of Hepato-Biliary and Pancreatic Surgery, Kanagawa Cancer Center, 1-1-2, Nakao, Yokohama City, Kanagawa Prefecture, Japan. kobayashis@kcch.ip

Abstract

OBJECTIVE:

Gemcitabine has been widely used, and cisplatin plus gemcitabine is considered as standard first-line chemotherapy for patients with advanced biliary tract cancer. However, no standard therapy was established following the progression to gemcitabine-containing first-line therapy. As S-1 monotherapy as second-line chemotherapy is still not well known in a practical setting this study aimed to clarify its efficacy and safety.

METHODS:

We retrospectively reviewed 55 consecutive patients who received S-1 monotherapy as second-line chemotherapy after failure of a gemcitabine-containing regimen at our institution from September 2007 to March 2011. The inclusion criteria were preserved organ function and an Eastern Cooperative Oncology Group performance status of 0-2 and without massive ascites or pleural effusion. S-1 was administered orally twice a day at a dose of 40 mg/m(2) for 28 days, followed by 14 days of rest.

RESULTS:

Fifty-one patients were selected for this analysis. The overall response rate was 4.0% and the disease control rate was 38.0%. The median survival time was 6.0 months and the median progression-free survival was 2.3 months. Adverse events were generally mild, and treatment-related death did not occur. In the subgroup analysis, overall survival was significantly shorter in the patients with peritoneal dissemination and those who had shown no response to the first-line chemotherapy (P= 0.033 and 0.023, respectively).

CONCLUSIONS:

S-1 monotherapy as the second-line chemotherapy for patients with gemcitabine-refractory advanced biliary tract cancer is also feasible in a practical setting and its efficacy is almost the same as in the previous prospective study.

PMID:
22826349
DOI:
10.1093/jjco/hys102
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Silverchair Information Systems
    Loading ...
    Support Center